This opportunity seeks to develop a bioprocessing system to stabilize live cell-based therapies without the need for ultra-cold storage, aiming to transform their manufacturing and distribution. The program also aims to accelerate advancements in related biotechnology areas like regenerative medicine and bio-surveillance. There are two distinct submission pathways: one for Performers with a solution summary due on February 19, 2026, and another for IV&V partners with a summary due on April 17, 2026. Several amendments have been issued to clarify proposal requirements, out-of-scope approaches, and reporting details. Interested parties must submit their solution summaries through a specified online portal.

This opportunity seeks to develop a bioprocessing system to stabilize live cell-based therapies without the need for ultra-cold storage, aiming to transform their manufacturing and distribution. The program also aims to accelerate advancements in areas like bio-surveillance, regenerative medicine, and blood product supply. For consideration as a Performer, a Solution Summary is required. For consideration as an IV&V partner, a separate Solution Summary is required. The work involves amendments to the Innovative Solutions Opening (ISO), including updates to capability requirements, allowable partner entities, and reporting deliverables.